01—Abstract
Summary
Summary of the 10-Q filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.
Guardant Health, Inc. reported a significant increase in total revenue for the second quarter and first half of 2024, driven primarily by its Precision Oncology Testing segment.
Total revenue for the three months ended June 30, 2024, rose by 29% year-over-year to $177.2 milliona, and for the six months ended June 30, 2024, revenue grew by 30% to $345.7 million. Despite revenue growth, the company continued to incur substantial net losses, with a loss of $102.6 million for the quarter and $217.6 million for the first half of the year.
This is a key area for investors to monitor, as is the company's substantial cash balance of $1.0 billionb as of June 30, 2024, which provides a sufficient runway for more than 12 months. A significant development during the period was the FDA approval and subsequent commercial launch of the Shield blood test for colorectal cancer screening in August 2024, positioning Guardant Health as a leader in early cancer detection.
02—Key points
Key Highlights
- Total revenue increased by 29% to $177.2 million for Q2 2024 and by 30% to $345.7 million for the first half of 2024, driven by strong performance in Precision Oncology Testing.
- Precision Oncology Testing revenue grew by 33% in Q2 and 35% in the first half, with both clinical and biopharmaceutical customer segments showing robust growth.
- The company reported a net loss of $102.6 million for Q2 2024 and $217.6 million for the first half of 2024, underscoring continued investment in growth and development.
- Guardant Health ended the period with a strong liquidity position, holding $1.0 billion in cash, cash equivalents, and restricted cash, providing over 12 months of operating runway.
- The Shield blood test received FDA approval in July 2024 and became commercially available in August 2024 for colorectal cancer screening, marking a significant milestone in early cancer detection.
- Research and Development expenses decreased by 8% year-over-year for Q2 and 9% for the first half, largely due to reduced clinical study costs.
- Sales and Marketing expenses increased by 15% in Q2 and 10% in the first half, reflecting investments in commercial infrastructure and marketing for new product launches.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2024, Guardant Health, Inc. lost $0.58.
- Revenue$177.2M100.0%
- Cost of revenue−$72.4M40.9%
- Gross profit$104.8M59.1%
- Operating costs−$205.4M115.9%
- Operating income−$100.6M56.8%
- Interest, other & tax−$2.0M1.1%
- Net income−$102.6M57.9%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 7, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $177.24M$137.15M | +29.2% |
| Cost of Revenue | $72.42M— | — |
| Gross Profit | $104.81M— | — |
| R&D Expenses | $83.10M$90.36M | −8.0% |
| Operating Expenses | $277.85M$256.77M | +8.2% |
| Operating Income | -$100.62M-$119.62M | +15.9% |
| Interest Expense | $645K$645K | 0.0% |
| Net Income | -$102.63M-$72.77M | −41.0% |
| EPS (Basic) | $-0.84$-0.67 | −25.4% |
| EPS (Diluted) | $-0.84$-0.67 | −25.4% |
| Shares Outstanding (Basic) | 122.45M108.81M | +12.5% |
| Shares Outstanding (Diluted) | 122.45M108.81M | +12.5% |
05—Questions
Frequently Asked Questions
What is the company's financial performance regarding revenue and profitability?
Guardant Health demonstrated strong revenue growth in the second quarter and first half of 2024, with total revenue increasing by 29% and 30% year-over-year, respectively. This growth was primarily driven by its Precision Oncology Testing segment. However, the company continued to report significant net losses, with a Q2 loss of $102.6 million and a first-half loss of $217.6 million, indicating ongoing investments in research, development, and commercialization.
What is the company's liquidity situation and outlook?
As of June 30, 2024, Guardant Health held approximately $1.0 billion in cash, cash equivalents, and restricted cash. Management believes this balance, along with anticipated cash flows, is sufficient to meet its requirements for more than 12 months. The company may seek additional capital in the future for expansion or strategic investments.
What are the key strategic developments or product updates mentioned in the filing?
A major highlight is the FDA approval and subsequent commercial launch of the Shield blood test for colorectal cancer screening in adults aged 45 and older in August 2024. This is the first FDA-approved blood test for primary colorectal cancer screening and also meets Medicare coverage requirements. The company continues to invest in R&D for future cancer screening technologies.
How are the company's operating expenses trending?
Research and Development expenses decreased slightly in Q2 and the first half of 2024, primarily due to lower clinical study costs. Conversely, Sales and Marketing expenses saw an increase, reflecting investments in commercial infrastructure and marketing efforts for existing and new products like the Shield test. General and administrative expenses remained relatively stable, with a slight decrease due to lower legal expenses.
06—Continue